

## Bristol-Myers Squibb – Update to recall of Eliquis® (apixaban)

- On June 17, 2017, the <u>FDA announced</u> that the recall of one lot of <u>Bristol-Myers Squibb's</u> <u>Eliquis</u>
   (<u>apixaban</u>) 5 mg tablets has been de-escalated from a consumer-level to a <u>retail/dispensing-level</u>
   recall.
  - Patients should not stop taking Eliquis without consulting with their physician.
- The recall was initiated due to a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets.
- The recalled lot was distributed in February 2017.

Product Description	NDC #	Lot # (Expiration date)
Eliquis (apixaban) 5 mg tablets, 60-count bottle	0003-0894-21	HN0063 (9/2019)

- Eliquis is indicated for the following: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; treatment of DVT and PE; and to reduce the risk of recurrent DVT and PE following initial therapy.
- Bristol-Myers Squibb has notified wholesalers and pharmacies to arrange for return and replacement
  of any recalled product. Consumers that have any recalled product should contact their healthcare
  provider and contact Bristol-Myers Squibb at 1-800-332-2056 for return and reimbursement
  information.
- Consumers should contact their healthcare provider if they have experienced any problems that may be related to taking Eliquis.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.